Lung cancer (Amsterdam, Netherlands) · 2026
Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsugitomi Ryosuke, Takagi Kento, Saito Go, Tachihara Motoko, Ashinuma Hironori, Shukuya Takehito, Takemoto Shinnosuke, Sakata Shinya, Mouri Atsuto, Miwa Hideki, Tamura Yosuke, Tokito Takaaki, Tsukita Yoko, Kogure Yoshihito, Masuda Takeshi, Tanaka Hiroshi, Kubo Sousuke, Sasaki Takaaki, Oba Tomohiro, Mamesaya Nobuaki, Yamanaka Taro, Nagashima Hiromi, Tamiya Motohiro, Kanemura Hiroaki, Tozuka Takehiro, Furuta Megumi, Kawachi Hayato, Ninomiya Takashi, Nagai Yoshiaki, Ogino Hirokazu, Ito Kentaro, Ishihara Masashi, Suzuki Takuji
Аннотация
BACKGROUND: Thymic carcinoma is a rare thoracic malignancy with limited first-line treatment options. Lenvatinib has shown efficacy and tolerability in previously treated patients, but its role in chemotherapy-naive patients is unclear.
METHODS: We conducted a retrospective, multicentre observational study across 31 Japanese institutions. Patients with advanced or recurrent thymic carcinoma who received lenvatinib between 23 March 2021 and 31 October 2022 were included. Data cut-off was 13 November 2024. Outcomes for chemotherapy-naive patients included objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), time to treatment failure (TTF), overall survival (OS), and adverse events (AEs). Subgroup analyses were stratified by age.
RESULTS: Of 107 patients, 20 received lenvatinib as first-line therapy. Median observation was 23.6 months (interquartile range, 12.5-27.1). ORR was 50% (90% confidence interval [CI], 27.2-72.8%), and DCR 85% (95% CI, 62.1-96.8%). Median PFS, TTF, and OS were 10.9 months (95% CI, 5.6-17.1), 8.9 months (95% CI, 5.3-17.8), and 25.0 months (95% CI, 21.2-not reached). AEs occurred in 95% (Grade ≥ 3 in 60%); dose reductions and discontinuations occurred in 85% and 25%. Safety was consistent with prior reports. Older patients showed higher rates of Grade ≥ 3 AEs and discontinuation.
CONCLUSIONS: In this real-world cohort, first-line lenvatinib demonstrated favourable efficacy and manageable safety, supporting its use in advanced or recurrent thymic carcinoma.
METHODS: We conducted a retrospective, multicentre observational study across 31 Japanese institutions. Patients with advanced or recurrent thymic carcinoma who received lenvatinib between 23 March 2021 and 31 October 2022 were included. Data cut-off was 13 November 2024. Outcomes for chemotherapy-naive patients included objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), time to treatment failure (TTF), overall survival (OS), and adverse events (AEs). Subgroup analyses were stratified by age.
RESULTS: Of 107 patients, 20 received lenvatinib as first-line therapy. Median observation was 23.6 months (interquartile range, 12.5-27.1). ORR was 50% (90% confidence interval [CI], 27.2-72.8%), and DCR 85% (95% CI, 62.1-96.8%). Median PFS, TTF, and OS were 10.9 months (95% CI, 5.6-17.1), 8.9 months (95% CI, 5.3-17.8), and 25.0 months (95% CI, 21.2-not reached). AEs occurred in 95% (Grade ≥ 3 in 60%); dose reductions and discontinuations occurred in 85% and 25%. Safety was consistent with prior reports. Older patients showed higher rates of Grade ≥ 3 AEs and discontinuation.
CONCLUSIONS: In this real-world cohort, first-line lenvatinib demonstrated favourable efficacy and manageable safety, supporting its use in advanced or recurrent thymic carcinoma.